» Articles » PMID: 9428617

Catecholamine-induced Cardiac Hypertrophy: Significance of Proto-oncogene Expression

Overview
Specialty General Medicine
Date 1998 Jan 15
PMID 9428617
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of beta- and alpha-adrenergic stimulation on cardiovascular function and development of cardiac hypertrophy was studied in rats by measuring the heart weight/body weight and cardiac RNA/DNA ratios. Beta-receptor stimulation with isoproterenol over 3 days induced an increase in the biosynthesis of cardiac adenine nucleotides, myocardial protein synthesis, and the heart weight/body weight ratio. The isoproterenol-induced metabolic effects were prevented by simultaneous beta-adrenergic blockade with propranolol. Alpha-adrenergic stimulation with norfenephrine for 3 days induced an increase in heart rate, total peripheral resistance, the myocardial RNA/DNA, and left ventricular weight/body weight ratio. The calcium antagonist verapamil prevented the hemodynamic changes but did not influence the development of cardiac hypertrophy. The alpha-adrenergic blocker prazosin reversed the norfenephrine-induced functional changes and prevented cardiac hypertrophy. Norepinephrine was infused into isolated perfused working rat hearts to elucidate some molecular biological changes that precede the development of cardiac hypertrophy. It increased transiently and sequentially the mRNA of c-fos and c-myc. This enhancement occurred at about the same time as that induced by elevation of pre- and afterload but was more pronounced. These findings were compared with those obtained in other studies assessing the effects of catecholamines on proto-oncogene expression. Combination of norepinephrine with pre- and afterload elevation induced the c-fos mRNA signal to appear earlier, to be more pronounced, and to persist for a longer period of time. Similar results were obtained in regard to the c-myc mRNA. These findings indicate that the combination of two hypertrophy-inducing stimuli which may cause a higher degree of cardiac hypertrophy in vivo induce an earlier, more pronounced, and longer lasting expression of the proto-oncogenes c-fos and c-myc.

Citing Articles

Isoproterenol induced cardiac hypertrophy: A comparison of three doses and two delivery methods in C57BL/6J mice.

Perez-Bonilla P, LaViolette B, Bhandary B, Ullas S, Chen X, Hirenallur-Shanthappa D PLoS One. 2024; 19(7):e0307467.

PMID: 39038017 PMC: 11262646. DOI: 10.1371/journal.pone.0307467.


Protective Effect of Uridine on Structural and Functional Rearrangements in Heart Mitochondria after a High-Dose Isoprenaline Exposure Modelling Stress-Induced Cardiomyopathy in Rats.

Belosludtseva N, Pavlik L, Mikheeva I, Talanov E, Serov D, Khurtin D Int J Mol Sci. 2023; 24(24).

PMID: 38139129 PMC: 10744270. DOI: 10.3390/ijms242417300.


An integral perspective of canonical cigarette and e-cigarette-related cardiovascular toxicity based on the adverse outcome pathway framework.

Ding R, Ren X, Sun Q, Sun Z, Duan J J Adv Res. 2022; 48:227-257.

PMID: 35998874 PMC: 10248804. DOI: 10.1016/j.jare.2022.08.012.


iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice.

Chen H, Wu M, Jiang W, Liu X, Zhang J, Yu C Int J Mol Med. 2020; 45(3):793-804.

PMID: 31985029 PMC: 7015125. DOI: 10.3892/ijmm.2020.4472.


Systematic evaluation of the adaptability of the non-radioactive SUnSET assay to measure cardiac protein synthesis.

Ravi V, Jain A, Ahamed F, Fathma N, Desingu P, Sundaresan N Sci Rep. 2018; 8(1):4587.

PMID: 29545554 PMC: 5854694. DOI: 10.1038/s41598-018-22903-8.